Human fibronectin extra domain B as a biomarker for targeted therapy in cancer

Autor: Damiënne Marcus, Evert J. Van Limbergen, Philippe Lambin, Alexander M A van der Wiel, Relinde I Y Lieverse, Ludwig Dubois, Ala Yaromina, Jan Theys
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Cancer Research
Angiogenesis
TUMOR VASCULATURE
medicine.medical_treatment
Review
Targeted therapy
Prostate cancer
angiogenesis
0302 clinical medicine
Neoplasms
METASTATIC MELANOMA
Molecular Targeted Therapy
biology
General Medicine
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
targeted therapy
3. Good health
PROSTATE-CANCER
Oncology
030220 oncology & carcinogenesis
Molecular Medicine
biomarker
FUSION PROTEIN L19-TNF
immunotherapy
RISK-STRATIFICATION
IMMUNOCYTOKINE L19-IL2
Diagnostic Imaging
Reviews
lcsh:RC254-282
RECOMBINANT ANTIBODY
03 medical and health sciences
Protein Domains
Genetics
medicine
Biomarkers
Tumor
cancer
Humans
INTERFERON-GAMMA
business.industry
Cancer
Immunotherapy
Radioimmunotherapy
medicine.disease
Review article
Fibronectins
Fibronectin
Biomarker
030104 developmental biology
TISSUE FACTOR
biology.protein
Cancer research
extra domain B
business
CELLULAR FIBRONECTIN
Zdroj: Molecular Oncology
Molecular Oncology, Vol 14, Iss 7, Pp 1555-1568 (2020)
ISSN: 1878-0261
1574-7891
Popis: The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some leukaemias. This domain, called the extra domain B (ED‐B), thus has broad therapeutic potential. The antibody L19 has been developed to specifically target ED‐B and has shown therapeutic potential when combined with cytokines, such as IL‐2. In this review article, we discuss the preclinical research and clinical trials that highlight the potential of ED‐B targeting for the imaging and treatment of various types of cancer. ED‐B‐centred studies also highlight how proper patient stratification is of utmost importance for the successful implementation of novel antibody‐based targeted therapies.
The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, the extra domain B (ED‐B). This review summarizes preclinical research and clinical trials on the potential of antibody‐based ED‐B targeting for tumour visualization and treatment.
Databáze: OpenAIRE
Externí odkaz: